Infectious agents were recently implicated in Alzheimer’s disease (AD) and etiology of other dementias, notably Helicobacter pylori. Read & Research Alzheimer’s More

Be the first to comment
            

Although Congress has allocated substantial funding to accelerate dementia research, nearly all attempts to find effective preventions and treatments for dementia have failed. Current dementia therapies offer little hope. They provide only modest clinical benefits and have limited impact on the unrelenting progression of disease. With few means to slow Read & Research Alzheimer’s More

Be the first to comment
            

The body needs vitamin B-12 for many processes. People with a deficiency may have neurological symptoms and fatigue, while an excess may indicate liver disease or diabetes. Doctors can use a vitamin B-12 level test to determine how much B-12 is in the body. Find out more about the test Read & Research Alzheimer’s More

Be the first to comment
            

Early-onset Alzheimer’s disease is a form of dementia that begins before the age of 65. Recognizing the initial symptoms can help a person seek treatment earlier and slow the progression of the disease. In this article, learn about ten signs of early-onset Alzheimer’s. We also cover how to help a Read & Research Alzheimer’s More

Be the first to comment
            

Cerebrospinal fluid (CSF) biomarkers have the potential to improve the diagnostic accuracy of Alzheimer’s disease, yet there is a lack of harmonized preanalytical CSF handling protocols. Read & Research Alzheimer’s More

Be the first to comment
            

Agitation is one of the most challenging neuropsychiatric symptoms to treat in Alzheimer’s disease and has significant implications for patient and caregiver. A major source of difficulty in identifying safe and effective treatments for agitation is the lack of validated biomarkers. As such, patients may not be appropriately targeted, and Read & Research Alzheimer’s More

Be the first to comment
            

Cognitive function is an important end point of treatments in dementia clinical trials. Measuring cognitive function by standardized tests, however, is biased toward highly constrained environments (such as hospitals) in selected samples. Patient-powered real-world evidence using information and communication technology devices, including environmental and wearable sensors, may help to overcome Read & Research Alzheimer’s More

Be the first to comment
            

Longitudinal studies are needed to understand the long-term associations between stroke and dementia. Read & Research Alzheimer’s More

Be the first to comment
            

A study of large sets of postmortem data provides new evidence that viruses — herpes HHV-6 and HHV-7 in particular — may be involved in Alzheimer’s. Read & Research Alzheimer’s More

Be the first to comment
            

Technology interventions are showing promise to assist persons with dementia and their carers. However, low adoption rates for these technologies and ethical considerations have impeded the realization of their full potential. Read & Research Alzheimer’s More

Be the first to comment
            

Helicobacter pylori infection might increase risk of dementia, but available evidence is inconsistent, and longitudinal studies are sparse. We investigated the association between H. pylori serology and dementia risk in a population-based cohort. Read & Research Alzheimer’s More

Be the first to comment
            

A study of brain CT scans of patients with memory problems found that diabetes and smoking were linked to hippocampal calcifications. Read & Research Alzheimer’s More

Be the first to comment
            

Hypertension in middle age is known to increase the risk of dementia, but so far the specifics are unclear. A new study sheds fresh light on this matter. Read & Research Alzheimer’s More

Be the first to comment
            

Precision medicine methodologies and approaches have advanced our understanding of the clinical presentation, development, progression, and management of Alzheimer’s disease (AD) dementia. However, sex and gender have not yet been adequately integrated into many of these approaches. Read & Research Alzheimer’s More

Be the first to comment
            

Editorial Board"> Editorial Board

Posted June 6, 2018 By

Read & Research Alzheimer’s More

Be the first to comment
            

Contents"> Contents

Posted June 6, 2018 By

Read & Research Alzheimer’s More

Be the first to comment
            

Heavy drinking is a risk factor for the development of Alzheimer’s. New research now reveals how alcohol may endanger the brain by impairing its defenses. Read & Research Alzheimer’s More

Be the first to comment
            

Memory naturally declines with age, but a new study shows that there may be an easy way to protect it — namely, by staying socially active. Read & Research Alzheimer’s More

Be the first to comment
            

Following an analysis of existing studies, researchers conclude that there is a link between depression and age-related cognitive decline. Read & Research Alzheimer’s More

Be the first to comment
            

There is one question often asked during scientific meetings, business travel, or dinner parties that is just as easily and equally posed by members of the research community, the general public, or by friends and family: what’s new in Alzheimer’s research? Today, there is growing interest from readers into the Read & Research Alzheimer’s More

Be the first to comment
            

Our objective was to investigate the effect of sex on cognitive decline within the context of amyloid β (Aβ) burden and apolipoprotein E genotype. Read & Research Alzheimer’s More

Be the first to comment
            

Young people should take better care of their hearing, new research warns, or they may expose themselves to a heightened risk of cognitive impairments. Read & Research Alzheimer’s More

Be the first to comment
            

Lifetime risks are the probabilities of progressing to Alzheimer’s disease (AD) dementia during one’s lifespan. Here, we report the first estimates of the lifetime and ten-year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease. Read & Research Alzheimer’s More

Be the first to comment
            

Genome-wide association studies consistently show that single nucleotide polymorphisms (SNPs) in the complement receptor 1 (CR1) gene modestly but significantly alter Alzheimer’s disease (AD) risk. Follow-up research has assumed that CR1 is expressed in the human brain despite a paucity of evidence for its function there. Alternatively, erythrocytes contain >80% Read & Research Alzheimer’s More

Be the first to comment
            

Both polymorphisms and mutations in glucocerebrosidase (GBA) may influence the development of dementia in patients with Parkinson’s disease. Read & Research Alzheimer’s More

Be the first to comment
            

Although the apolipoprotein E ε4-allele (APOE-ε4) is a susceptibility factor for Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), its relationship with imaging and cognitive measures across the AD/DLB spectrum remains unexplored. Read & Research Alzheimer’s More

Be the first to comment
            

In March, a $414 million increase for Alzheimer’s disease (AD) and dementia research funding at the National Institutes of Health and Kevin and Avonte’s Law, important legislation to protect those who wander, were signed into law. Read & Research Alzheimer’s More

Be the first to comment
            

A landmark study sheds light on the underlying mechanisms that impact neural health in Parkinson’s disease and dementia. Can it lead to better treatments? Read & Research Alzheimer’s More

Be the first to comment
            

The interplay between midlife vascular risk factors and midlife cognitive function with later life mild cognitive impairment (MCI) and dementia (DEM) is not well understood. Read & Research Alzheimer’s More

Be the first to comment
            

According to the latest study, cholesterol plays a role in the formation of plaques in Alzheimer’s disease. The findings open new avenues for drug design. Read & Research Alzheimer’s More

Be the first to comment